Compare WST & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WST | LII |
|---|---|---|
| Founded | 1923 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.5B | 15.8B |
| IPO Year | 2004 | 1999 |
| Metric | WST | LII |
|---|---|---|
| Price | $303.47 | $488.69 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 13 |
| Target Price | $320.86 | ★ $566.58 |
| AVG Volume (30 Days) | ★ 829.5K | 455.0K |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | 0.28% | ★ 1.05% |
| EPS Growth | ★ 1.49 | 1.11 |
| EPS | 1.92 | ★ 22.79 |
| Revenue | $2,886,900,000.00 | ★ $5,195,300,000.00 |
| Revenue This Year | $6.76 | $6.85 |
| Revenue Next Year | $6.22 | $5.76 |
| P/E Ratio | $45.57 | ★ $21.69 |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $203.74 | $434.06 |
| 52 Week High | $322.34 | $689.44 |
| Indicator | WST | LII |
|---|---|---|
| Relative Strength Index (RSI) | 75.56 | 50.42 |
| Support Level | $234.43 | $479.34 |
| Resistance Level | $322.34 | $498.78 |
| Average True Range (ATR) | 7.67 | 17.05 |
| MACD | 4.11 | 2.36 |
| Stochastic Oscillator | 75.29 | 56.16 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Lennox International manufacturers and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounted for 67% of sales and commercial HVAC (building climate solutions) accounted for the remaining 33% of sales. To be clear, Lennox's commercial exposure is what its peers refer to as "residential and light commercial," lacks the scale and complexity of what is referred to as an "applied" solution. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand.